Lifevantage (NASDAQ:LFVN) Stock Rating Lowered by Wall Street Zen

Key Points

• Lifevantage stock has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, indicating a more cautious outlook from analysts.
• The company reported quarterly earnings of $0.17 per share, meeting expectations, but fell short on revenue with $55.11 million compared to a consensus estimate of $57.93 million.
• Insider trading activity included Director Michael A. Beindorff selling 4,125 shares, reducing his ownership by 15.29% and reflecting a potential shift in insider confidence.

Lifevantage (NASDAQ:LFVN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Friday.

Separately, Weiss Ratings reiterated a "hold (c+)" rating on shares of Lifevantage in a research note on Saturday, September 27th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.50.

Lifevantage Stock Down 0.9%

Shares of NASDAQ LFVN traded down $0.09 on Friday, reaching $9.48. 86,038 shares of the company's stock traded hands, compared to its average volume of 201,654. The business's 50 day simple moving average is $12.13 and its two-hundred day simple moving average is $12.83. Lifevantage has a 12 month low of $9.44 and a 12 month high of $27.38. The company has a market cap of $120.30 million, a price-to-earnings ratio of 12.81 and a beta of 0.26.

Lifevantage (NASDAQ:LFVN - Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. The company had revenue of $55.11 million for the quarter, compared to the consensus estimate of $57.93 million. Lifevantage had a return on equity of 33.75% and a net margin of 4.29%.During the same quarter in the prior year, the business posted $0.14 EPS. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Insider Activity

In other Lifevantage news, Director Michael A. Beindorff sold 4,125 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total transaction of $47,190.00. Following the completion of the sale, the director directly owned 22,858 shares in the company, valued at $261,495.52. The trade was a 15.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 21.95% of the stock is currently owned by corporate insiders.

Institutional Trading of Lifevantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its stake in shares of Lifevantage by 5.4% during the 1st quarter. Jane Street Group LLC now owns 36,567 shares of the company's stock worth $533,000 after acquiring an additional 1,877 shares during the last quarter. Farther Finance Advisors LLC bought a new position in Lifevantage in the 2nd quarter worth $25,000. Cetera Investment Advisers lifted its position in Lifevantage by 10.8% during the second quarter. Cetera Investment Advisers now owns 20,098 shares of the company's stock valued at $263,000 after purchasing an additional 1,954 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Lifevantage during the second quarter valued at $31,000. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Lifevantage by 23.2% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company's stock valued at $188,000 after purchasing an additional 2,421 shares during the period. 35.32% of the stock is owned by hedge funds and other institutional investors.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.